Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 with Methionine-Restricted Diet in Metastatic TNBC
NCT03733119Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abrocitinib in triple-negative breast cancer (TNBC), sponsored by University of Wisconsin–Madison. Started Nov 2018; status: terminated.
02
Drugs
abrocitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03733119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733119.